EVAX

Evaxion A/S American Depositary Share (EVAX) | Rumor.io

Evaxion A/S

EVAX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,631

Bullish sentiment (50-day avg)89%

Price to earnings ratio-3.23

Market capitalization29.2M

Earnings per share-0.49

Dividend yield (TTM)—

Revenue (annual)7.5M

Net income (annual)-7.7M

Social

What share of all stock conversation is about EVAX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 20

Evaxion Biotech A/S has expanded its pipeline with EVX-05, a cancer vaccine program targeting glioblastoma, a deadly brain cancer.
The EVX-05 glioblastoma vaccine represents a significant step forward in the high-risk cancer treatment market, with a strategic shift in Evaxion's product portfolio.
Evaxion has secured funding through the second half of 2027, supporting its continued development of the EVX-05 program.

Generated by AI

Sentiment

Of the messages about EVAX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	93.75% +12.14
Bearish	—	—	—	6.25% -12.14

Bullish· Aug 20

$EVAX is setting up for a potential rise after the recent phase 2 data announcement, with the author expecting a slow and steady increase.
The company has enough cash until the end of 2027, reducing the risk of financial distress and increasing the likelihood of a successful future.
There is a significant accumulation of shares, with the author noting a deep accumulation and a relative volume of $380 X, suggesting that the stock could potentially double in value.

Bearish· Sep 25

The author is shorting EVAX and believes the price will drop due to longs being trapped after a positive news announcement.
The shorts have been rejected three times, but the author believes they are almost exhausted and will be done soon.
The author thinks EVAX is very cheap and wants to see a price of $30 today, implying that the current price is undervalued.

Generated by AI

Topics

Of the messages about EVAX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	83.59%
Technical Analysis	—	—	—	13.77%
Earnings	—	—	—	0.22%
Analysts	—	—	—	2.42%
Controversies	—	—	—	0%
Macro	—	—	—	0%

Announcements· Sep 25

Evaxion Biotech A/S has partnered with Merck on its vaccine candidate EVX-B3, a significant validation of the company's AI-powered vaccine platform.
The partnership has the potential to bring in $592M in milestone and royalty payments, in addition to the $7.5M upfront license fee.
The partnership targets a novel pathogen associated with repeated infections and serious medical complications, for which there are currently no available vaccines.

Technical Analysis· Sep 25

$EVAX has formed a triple bottom and tested VWAP several times, with potential for an uptrend if it breaks VWAP and stays steady.
A news stock like $EVAX, currently below the 200-day moving average, must hold this level or risk being out of play.
$EVAX is in a squeeze scenario, with a potential breakout to $6 and a strong uptrend indicated by technical indicators such as ADX and RSI.

Generated by AI

Community

Of the messages about EVAX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	61.39%
Newcomers	—	—	100%	38.61%

Regulars· Aug 20

The company is expected to release extended phase 2 data in October, which could lead to a slow and steady rise in stock price.
The regulars are optimistic about the stock's potential, with one user stating it's "setting up nicely" and another predicting it will either reach $10 or drop to $1 on a given day.
The company's business update and second-quarter 2026 financial results are scheduled for August 20, 2026, at 2:30 PM CET/8:30 AM ET.

Newcomers· Aug 20

Newcomers are discussing the significance of Evaxion's addition of a new glioblastoma vaccine, which represents a step forward in the high-risk cancer treatment market.
Many are focused on the company's pipeline expansion and its partnership with Duke University to develop the EVX-05 glioblastoma vaccine.
Others are speculating about the potential price movement of EVAX, with some predicting a rise to $10, $12, or even breaking through $20-$25.

Generated by AI

News

Evaxion expands AI platform to autoimmune disease treatments

15d agoInvesting.com

Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX) and Boston Scientific (BSX)

Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Analysts’ Top Healthcare Picks: Evaxion Biotech (EVAX), Ultragenyx Pharmaceutical (RARE)

Detailed price information for Ultragenyx Pharmaceu (RARE-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Can Merck & Company (MRK)’s Stake in Evaxion A/S (EVAX) Validate the Potential of AI-Driven Vaccine Discovery?

In a regulatory filing on August 10, pharmaceutical titan Merck & Company, Inc. (NYSE:MRK) disclosed holding 1,214,126 shares of micro-cap AI immunology firm Evaxion A/S (NASDAQ:EVAX). Evaxion shares bumped up 2% to $3.17 in early trading on the news. The position follows Merck’s September 2025 decision to exercise its option to in-license EVX-B3, Evaxion’s discovery-stage […]

1mo agoYahoo Finance

Earnings call transcript: Evaxion shares rise on Q2 2026 pipeline progress

1mo agoInvesting.com

Evaxion Biotech Q2 2026 Earnings Call: Complete Transcript

1mo agoBenzinga

Also Discussed

Investors talking about EVAX also mention

#	Name	Attention
1	FAT Brands Inc. Class B Common StockFATBB	0%0
2	Pasithea Therapeutics Corp.KTTA	0%0
3	LIPO - Lipella Pharmaceuticals Inc.	——
4	ALUR - Allurion Technologies Inc.	——
5	Cumberland Pharmaceuticals Inc.CPIX	0%new
6	PRF Technologies Ltd.PRFX	0%+0
7	Vivos Therapeutics, Inc.VVOS	0%+0
8	American BriVision (Holding) CorporationABVC	0%+0
9	CRGX - CARGO Therapeutics, Inc. Common Stock	——
10	DICE - DICE Therapeutics, Inc.	——

Evaxion A/S American Depositary Share

Healthcare
Biotechnology

Evaxion A/S American Depositary Share represents ownership in Evaxion A/S, a Denmark-based clinical-stage biotechnology company focused on AI-immunology powered vaccines. The company develops artificial intelligence-driven solutions for discovering and designing vaccines and immunotherapies aimed at cancer and infectious diseases. Its current work centers on using proprietary platforms to analyze immune-system data and support the creation of vaccine candidates for oncology, bacterial disease, and viral disease applications. Evaxion operates as a techbio company at the intersection of biotechnology and artificial intelligence, combining computational methods with immunology research to advance drug discovery. Through its American Depositary Shares, investors gain access to a company whose business is built around vaccine development and immune-based therapeutic research in the global healthcare market.

Website

Location

Dr. Neergaards Vej

Horsholm, 2970

Denmark

Social

What share of all stock conversation is about EVAX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 20

Evaxion Biotech A/S has expanded its pipeline with EVX-05, a cancer vaccine program targeting glioblastoma, a deadly brain cancer.
The EVX-05 glioblastoma vaccine represents a significant step forward in the high-risk cancer treatment market, with a strategic shift in Evaxion's product portfolio.
Evaxion has secured funding through the second half of 2027, supporting its continued development of the EVX-05 program.

Generated by AI

Sentiment

Of the messages about EVAX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	93.75% +12.14
Bearish	—	—	—	6.25% -12.14

Bullish· Aug 20

$EVAX is setting up for a potential rise after the recent phase 2 data announcement, with the author expecting a slow and steady increase.
The company has enough cash until the end of 2027, reducing the risk of financial distress and increasing the likelihood of a successful future.
There is a significant accumulation of shares, with the author noting a deep accumulation and a relative volume of $380 X, suggesting that the stock could potentially double in value.

Bearish· Sep 25

The author is shorting EVAX and believes the price will drop due to longs being trapped after a positive news announcement.
The shorts have been rejected three times, but the author believes they are almost exhausted and will be done soon.
The author thinks EVAX is very cheap and wants to see a price of $30 today, implying that the current price is undervalued.

Generated by AI

Topics

Of the messages about EVAX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	83.59%
Technical Analysis	—	—	—	13.77%
Earnings	—	—	—	0.22%
Analysts	—	—	—	2.42%
Controversies	—	—	—	0%
Macro	—	—	—	0%

Announcements· Sep 25

Evaxion Biotech A/S has partnered with Merck on its vaccine candidate EVX-B3, a significant validation of the company's AI-powered vaccine platform.
The partnership has the potential to bring in $592M in milestone and royalty payments, in addition to the $7.5M upfront license fee.
The partnership targets a novel pathogen associated with repeated infections and serious medical complications, for which there are currently no available vaccines.

Technical Analysis· Sep 25

$EVAX has formed a triple bottom and tested VWAP several times, with potential for an uptrend if it breaks VWAP and stays steady.
A news stock like $EVAX, currently below the 200-day moving average, must hold this level or risk being out of play.
$EVAX is in a squeeze scenario, with a potential breakout to $6 and a strong uptrend indicated by technical indicators such as ADX and RSI.

Generated by AI

Community

Of the messages about EVAX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	61.39%
Newcomers	—	—	100%	38.61%

Regulars· Aug 20

The company is expected to release extended phase 2 data in October, which could lead to a slow and steady rise in stock price.
The regulars are optimistic about the stock's potential, with one user stating it's "setting up nicely" and another predicting it will either reach $10 or drop to $1 on a given day.
The company's business update and second-quarter 2026 financial results are scheduled for August 20, 2026, at 2:30 PM CET/8:30 AM ET.

Newcomers· Aug 20

Newcomers are discussing the significance of Evaxion's addition of a new glioblastoma vaccine, which represents a step forward in the high-risk cancer treatment market.
Many are focused on the company's pipeline expansion and its partnership with Duke University to develop the EVX-05 glioblastoma vaccine.
Others are speculating about the potential price movement of EVAX, with some predicting a rise to $10, $12, or even breaking through $20-$25.

Generated by AI

Evaxion A/S

Social

Aug 20

Bullish· Aug 20

Bearish· Sep 25

Announcements· Sep 25

Technical Analysis· Sep 25

Regulars· Aug 20

Newcomers· Aug 20

Evaxion expands AI platform to autoimmune disease treatments

Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX) and Boston Scientific (BSX)

Analysts’ Top Healthcare Picks: Evaxion Biotech (EVAX), Ultragenyx Pharmaceutical (RARE)

Can Merck & Company (MRK)’s Stake in Evaxion A/S (EVAX) Validate the Potential of AI-Driven Vaccine Discovery?

Earnings call transcript: Evaxion shares rise on Q2 2026 pipeline progress

Evaxion Biotech Q2 2026 Earnings Call: Complete Transcript

Also Discussed

Evaxion A/S American Depositary Share

Company Information

Location

Evaxion expands AI platform to autoimmune disease treatments

Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX) and Boston Scientific (BSX)

Analysts’ Top Healthcare Picks: Evaxion Biotech (EVAX), Ultragenyx Pharmaceutical (RARE)

Can Merck & Company (MRK)’s Stake in Evaxion A/S (EVAX) Validate the Potential of AI-Driven Vaccine Discovery?

Earnings call transcript: Evaxion shares rise on Q2 2026 pipeline progress

Evaxion Biotech Q2 2026 Earnings Call: Complete Transcript

Also Discussed

Social

Aug 20

Bullish· Aug 20

Bearish· Sep 25

Announcements· Sep 25

Technical Analysis· Sep 25

Regulars· Aug 20

Newcomers· Aug 20